Literature DB >> 24251076

Properties and mutation studies of a bacteriophage-derived chimeric recombinant staphylolytic protein P128: Comparison to recombinant lysostaphin.

Sanjeev Rajagopalan Saravanan1, Vivek Daniel Paul, Shilpa George, Sudarson Sundarrajan, Nirmal Kumar, Madhavi Hebbur, Naveen Kumar, Ananda Veena, Uma Maheshwari, Chemira Biddappa Appaiah, Muralidharan Chidambaran, Anuradha Gopal Bhat, Sukumar Hariharan, Sriram Padmanabhan.   

Abstract

P128 is a chimeric anti-staphylococcal protein having a catalytic domain from a Staphylococcus bacteriophage K tail associated structural protein and a cell wall targeting domain from the Staphylococcus bacteriocin-lysostaphin. In this study, we disclose additional properties of P128 and compared the same with lysostaphin. While lysostaphin was found to get inactivated by heat and was inactive on its parent strain S. simulans biovar staphylolyticus, P128 was thermostable and was lytic towards S. simulans biovar staphylolyticus demonstrating a difference in their mechanism of action. Selected mutation studies of the catalytic domain of P128 showed that arginine and cysteine, at 40th and 76th positions respectively, are critical for the staphylolytic activity of P128, although these amino acids are not conserved residues. In comparison to native P128, only the R40S mutant (P301) was catalytically active on zymogram gel and had a similar secondary structure, as assessed by circular dichroism analysis and in silico modeling with similar cell binding properties. Mutation of the arginine residue at 40th position of the P128 molecule caused dramatic reduction in the Vmax (∆OD600 [mg/min]) value (nearly 270 fold) and the recombinant lysostaphin also showed lesser Vmax value (nearly 1.5 fold) in comparison to the unmodified P128 protein. The kinetic parameters such as apparent Km (KmAPP) and apparent Kcat (KcatAPP) of the native P128 protein also showed significant differences in comparison to the values observed for P301 and lysostaphin.

Entities:  

Keywords:  Staphylococcus aureus; arginine mutation; disulfide bonds; in silico modeling; methicillin resistance; western blot

Year:  2013        PMID: 24251076      PMCID: PMC3827070          DOI: 10.4161/bact.26564

Source DB:  PubMed          Journal:  Bacteriophage        ISSN: 2159-7073


  55 in total

Review 1.  Thermozymes and their applications: a review of recent literature and patents.

Authors:  M E Bruins; A E Janssen; R M Boom
Journal:  Appl Biochem Biotechnol       Date:  2001-02       Impact factor: 2.926

2.  Factors enhancing protein thermostability.

Authors:  S Kumar; C J Tsai; R Nussinov
Journal:  Protein Eng       Date:  2000-03

3.  Determination of lysozyme activities in a microplate format.

Authors:  Yuan C Lee; Derek Yang
Journal:  Anal Biochem       Date:  2002-11-15       Impact factor: 3.365

Review 4.  The CHAP domain: a large family of amidases including GSP amidase and peptidoglycan hydrolases.

Authors:  Alex Bateman; Neil D Rawlings
Journal:  Trends Biochem Sci       Date:  2003-05       Impact factor: 13.807

Review 5.  Amidase domains from bacterial and phage autolysins define a family of gamma-D,L-glutamate-specific amidohydrolases.

Authors:  Daniel J Rigden; Mark J Jedrzejas; Michael Y Galperin
Journal:  Trends Biochem Sci       Date:  2003-05       Impact factor: 13.807

6.  Virolysin: a virus-induced lysin from staphylococcal phage lysates.

Authors:  D J RALSTON; B S BAER; M LIEBERMAN; A P KRUEGER
Journal:  Proc Soc Exp Biol Med       Date:  1955-08

7.  Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus.

Authors:  M W Climo; K Ehlert; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

8.  Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate.

Authors:  S Boyle-Vavra; R B Carey; R S Daum
Journal:  J Antimicrob Chemother       Date:  2001-11       Impact factor: 5.790

Review 9.  Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus.

Authors:  F C Tenover; J W Biddle; M V Lancaster
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883

10.  Evolutionary history, structural features and biochemical diversity of the NlpC/P60 superfamily of enzymes.

Authors:  Vivek Anantharaman; L Aravind
Journal:  Genome Biol       Date:  2003-02-03       Impact factor: 13.583

View more
  5 in total

Review 1.  Bacteriophage-encoded virion-associated enzymes to overcome the carbohydrate barriers during the infection process.

Authors:  Agnieszka Latka; Barbara Maciejewska; Grazyna Majkowska-Skrobek; Yves Briers; Zuzanna Drulis-Kawa
Journal:  Appl Microbiol Biotechnol       Date:  2017-03-23       Impact factor: 4.813

Review 2.  Phage-Derived Peptidoglycan Degrading Enzymes: Challenges and Future Prospects for In Vivo Therapy.

Authors:  Hugo Oliveira; Carlos São-José; Joana Azeredo
Journal:  Viruses       Date:  2018-05-29       Impact factor: 5.048

Review 3.  Engineering of Phage-Derived Lytic Enzymes: Improving Their Potential as Antimicrobials.

Authors:  Carlos São-José
Journal:  Antibiotics (Basel)       Date:  2018-03-22

4.  GMEnzy: a genetically modified enzybiotic database.

Authors:  Hongyu Wu; Jinjiang Huang; Hairong Lu; Guodong Li; Qingshan Huang
Journal:  PLoS One       Date:  2014-08-01       Impact factor: 3.240

Review 5.  Treating Bacterial Infections with Bacteriophage-Based Enzybiotics: In Vitro, In Vivo and Clinical Application.

Authors:  Katarzyna M Danis-Wlodarczyk; Daniel J Wozniak; Stephen T Abedon
Journal:  Antibiotics (Basel)       Date:  2021-12-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.